Minoryx Press Release
2025-03-04

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

Minoryx announces dosing of the…
read more
Minoryx Press Release
2023-06-05

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

US trial with leriglitazone to…
read more
Minoryx Press Release
2023-04-25

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

Initial evidence of disease stabilization…
read more
Minoryx Press Release
2022-11-10

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe9

The companies enter into a…
read more
Minoryx Press Release
2022-09-20

Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD

Minoryx‘s Marketing Authorization Application for…
read more
Minoryx Press Release
2022-05-31

Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

Minoryx raises €51 million to…
read more
Minoryx Press Release
2021-11-03

Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

Presentation highlights reduction in cerebral…
read more
Minoryx Press Release
2021-06-03

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

Minoryx publishes mechanism of action…
read more
Minoryx Press Release
2021-04-12

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting

Minoryx Phase 2/3 ‘ADVANCE’ study…
read more
Minoryx Press Release
2021-02-17

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news
read more